SciSparc Ltd. Reports Key Clinical Trial Approval Renewal - Form 6-K, Dec 31, 2024

Here are the key insights extracted from the provided section of the financial report:

1. Company Name: SciSparc Ltd.
   
2. Type of Filing: This document is a Form 6-K, which is a report of a foreign private issuer.
3. Date of Report: The report is dated December 31, 2024.
4. Commission File Number: 001-38041.
5. Address: The company's principal executive offices are located at 20 Raul Wallenberg Street, Tower A, Tel Aviv 6971916, Israel.
6. Content Summary:

• The report states that on December 31, 2024, SciSparc Ltd. issued a press release announcing the renewal of approval by the Israeli Medical Cannabis Agency for its clinical trial focused on children with Autism Spectrum Disorder.
• The press release is included as Exhibit 99.1 to the report.

7. Registration Statements: The report is incorporated by reference into the company’s registration statements on Form F-3 and Form S-8, with several file numbers provided.
8. Signatures: The report has been signed by Oz Adler, who holds the positions of Chief Executive Officer and Chief Financial Officer of SciSparc Ltd.

This information is significant as it highlights an important regulatory update regarding clinical trials, which may impact the company's operations and investor sentiment. The renewal of approval from the Israeli Medical Cannabis Agency could signify progress in the company’s research and development efforts.